

Letter to the Editor

Considerations about the genetics of left ventricular hypertrabeculation/non-compaction

Keywords: Non-compaction; unclassified cardiomyopathy; genetics; neuromuscular disorder

Received: 7 February 2015; Accepted: 11 April 2015; First published online: 22 June 2015

Left ventricular hypertrabeculation is a cardiac abnormality increasingly recognised by neurologists as well. According to the American Heart Association/European Heart Association guidelines, left ventricular hypertrabeculation, also known as left ventricular non-compaction or non-compaction, is an unclassified cardiomyopathy characterised by a regionally bi-layered left ventricular myocardium distal to the papillary muscles.¹ The endocardial layer is thicker than the epicardial layer and is characterised by a meshwork of interwoven myocardial strands lined with endocardium. The epicardial layer is thinner than the endocardial layer and is compacted.² Spaces between trabeculations are perfused from the ventricular side, but the non-physiological flow facilitates thrombus formation. Non-compaction may occur in isolation without other cardiac diseases or together with other cardiac abnormalities – such as hypertrophic, dilated, or restrictive cardiomyopathies – or cardiac malformations – such as Ebstein's anomaly, tetralogy of Fallot, ventricular septal defect, atrial septal defect, hypoplastic right ventricle, non-compaction of the right ventricle, myocardial bridges, absence of the pericardium, mitral valve prolapse, tricuspid atresia, pulmonary atresia, bi-cuspid aortic valve, congenital aortic stenosis, double-orifice mitral valve, aortic interruption, patent ductus arteriosus, congenital atresia of the coronary arteries, or coronary aneurysms. Non-compaction is usually asymptomatic but can be complicated by cardiac embolism, ventricular arrhythmias with sudden cardiac death, or heart failure.³

The aetiology of non-compaction is unknown, but in the majority of cases it is speculated to result from non-compaction of the myocardium during embryogenesis. This assumption is challenged by patients who are diagnosed with non-compaction in

adulthood but do not show non-compaction on previous echocardiographies (acquired non-compaction).⁴ In addition, 7% of primigravida develop non-compaction during pregnancy, and 25% develop hypertrabeculation, although the differentiation between non-compaction and hypertrabeculation in the latter study is unclear.⁵ Non-compaction has also been observed 2 weeks post-partum.⁶ A third argument that supports the hypothesis that non-compaction is not only congenital is the observation that athletes develop hypertrabeculation of the left ventricle when performing extreme exercise training.⁷ In pregnant females, the development of non-compaction was attributed to increased pre-load conditions.⁵ Several other speculations such as reduced adhesion of cardiomyocytes, frustrate attempt to overcome a metabolic defect, weak myocardium, micro-infarction, adaptation to increased stroke volumes, or enlargement of the endocardium to improve oxygenation have been raised to explain acquired non-compaction.⁴ In rare cases, non-compaction may disappear over time.⁸

Non-compaction is frequently associated with a variety of different neuromuscular disorders (Table 1),⁹ but no causal relationship between non-compaction and any neuromuscular disorder has been established so far. A strong argument against a causal relationship is that non-compaction occurs only in a minority of patients with neuromuscular disorders, even when they are systematically screened for non-compaction. A further argument against a causal relationship is the large variability of neuromuscular disorders that are associated with non-compaction, suggesting a compensatory rather than a causal mechanism. An argument in favour of a hereditary cause, however, is the familial occurrence of non-compaction.¹⁰ As up to 80% of the patients with non-compaction are associated with a neuromuscular disorder,¹¹ it is recommended to screen non-compaction patients systematically for neuromuscular disorders.¹¹

Correspondence to: J. Finsterer, MD, PhD, Postfach 20, 1180 Vienna, Austria.
Tel: +431 711 659 2085; Fax: +431 478 1711; E-mail: ffigs1@yahoo.de

Table 1. Human NMDs and cardiomyopathy associated with LVHT

NMD	Mutated gene
MDs	
Duchenne MD	Dystrophin
Becker MD	Dystrophin
Duchenne carrier	Dystrophin
Myotonic dystrophy 1	DMPK
Myotonic dystrophy 2	ZNF9
Emery–Dreifuss MD, laminopathy	LMNA
Dystrobrevinopathy	α-DTNA
Zasopathy	Cypher-ZASP/LDB3
Oculopharyngodistal MD	Unknown
Congenital myopathies	
Nemaline myopathy	TPM1
Multi-minicore disease	RYR1
Integrin myopathy	ITGA7
Congenital fibre type disproportion	MYH7B
MYH7 myopathy	MYH7
Metabolic myopathies	
Danon disease (glycogenosis IIb)	LAMP2
Pompe disease (glycogenosis type IIa)	GAA
Glycogen storage disease type IV	GBE1
Myoadenylate-deaminase deficiency	AMPD1
Mitochondrial myopathies	mtDNA genes, nDNA genes
Succinate dehydrogenase deficiency	SDH
Very long-chain fatty acid oxidation disease	Not provided
MCD	Not provided
Glycogenosis Ib	Not provided
Other hereditary myopathies	
Barth syndrome	TAZ
Barth carrier	TAZ
Cobalamin C disease, methylmalonic aciduria	MMACHC
Hereditary inclusion body myositis	Not provided
Myopathy with spherocytosis	Not provided
Dystrophic epidermolysis bullosa	COL7A1
Epidermolysis bullosa simplex	PLEC1
Congenital myopathy	MYH7B
Neuropathies/neuroopathies	
Charcot–Marie–Tooth neuropathy type 1A	PMP22
Friedreich ataxia	FXN
Beta-thalassaemia	β-globin
Fabry disease	GLA
Other cardiac disease	
CMP	ACTC1
CMP	TNNT2
CMP	TNNI3
CMP	MYBPC3
CMP	DNAJC19
Arrhythmias	SCNA5
CMP	PTPN11 (SHP2)
Non-hereditary NMDs	
Poliomyelitis	Non-hereditary
Sporadic inclusion body myositis	Non-hereditary

CMP = cardiomyopathy; LVHT = left ventricular hypertrabeculation;
MCD = malonyl coenzyme (COA) decarboxylase deficiency;
MDs = muscular dystrophies; NMD = neuromuscular disorder

Neuromuscular disorders most frequently associated with non-compaction are the mitochondrial disorders followed by Barth syndrome, Duchenne muscular

dystrophy, and myotonic dystrophy 1.¹² In addition to neuromuscular disorders, non-compaction is frequently associated with cardiomyopathies other than non-compaction and with chromosomal defects.¹²

For the neurologist, it is important to be familiar with non-compaction for two reasons: first, patients with non-compaction are potential neuromuscular disorder patients, and thus they should be thoroughly investigated for overt or sub-clinical neuromuscular disorders. Second, neuromuscular disorder patients frequently present with cardiac involvement, of which non-compaction is one of the possible manifestations. As the presence of non-compaction in a neuromuscular disorder patient has prognostic implications, it is advisable to screen neuromuscular disorder patients for this cardiac abnormality and to institute appropriate therapeutic measures, including oral anticoagulation in case of non-compaction and atrial fibrillation or non-compaction and heart failure or systolic dysfunction, implantation of an implantable cardioverter defibrillator in case of ventricular arrhythmias, or to initiate heart failure therapy or heart transplantation in case of intractable heart failure.

Josef Finsterer
Krankenanstalt Rudolfstiftung
Vienna, Austria

Sinda Zarrouk-Mahjoub
Genomics Platform
Pasteur Institute of Tunis
Tunisia

References

- Maron BJ, Towbin JA, Thiene G, et al. American Heart Association; Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; Council on Epidemiology and Prevention. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. *Circulation* 2006; 113: 1807–1816.
- Stöllberger C, Gerecke B, Finsterer J, Engberding R. Refinement of echocardiographic criteria for left ventricular noncompaction. *Int J Cardiol* 2013; 165: 463–467.
- Stöllberger C, Blazek G, Wegner C, Winkler-Dworak M, Finsterer J. Neuromuscular and cardiac comorbidity determines survival in 140 patients with left ventricular hypertrabeculation/noncompaction. *Int J Cardiol* 2011; 150: 71–74.
- Finsterer J, Stöllberger C, Schubert B. Acquired left ventricular noncompaction as a cardiac manifestation of neuromuscular disorders. *Scand Cardiovasc J* 2008; 42: 25–30.
- Gati S, Papadakis M, Papamichael ND, et al. Reversible de novo left ventricular trabeculations in pregnant women: implications for the diagnosis of left ventricular noncompaction in low-risk populations. *Circulation* 2014; 130: 475–483.

- 6 Rehfeldt KH, Pulido JN, Mauermann WJ, Click RL. Left ventricular hypertrabeculation/noncompaction in a patient with peripartum cardiomyopathy. *Int J Cardiol* 2010; 139: e18–e20.
- 7 Peritz DC, Vaughn A, Ciocca M, Chung EH. Hypertrabeculation vs left ventricular noncompaction on echocardiogram: a reason to restrict athletic participation? *JAMA Intern Med* 2014; 174: 1379–1382.
- 8 Stöllberger C, Kolussi T, Hackl M, et al. Disappearance of left ventricular hypertrabeculation/noncompaction in vacuolar non-neuromuscular cardiomyopathy. *Int J Cardiol* 2015; 179: 5–8.
- 9 Finsterer J, Stöllberger C, Brandau O, Laccone F, Bichler K, Laing NG. Novel MYH7 mutation associated with mild myopathy but life-threatening ventricular arrhythmias and noncompaction. *Int J Cardiol* 2014; 173: 532–535.
- 10 Basu R, Hazra S, Shanks M, Paterson DI, Oudit GY. Novel mutation in exon 14 of the sarcomere gene MYH7 in familial left ventricular noncompaction with bicuspid aortic valve. *Circ Heart Fail* 2014; 7: 1059–1062.
- 11 Stöllberger C, Finsterer J, Blazek G. Left ventricular hypertrabeculation/noncompaction and association with additional cardiac abnormalities and neuromuscular disorders. *Am J Cardiol* 2002; 90: 899–902.
- 12 Finsterer J. Cardiogenetics, neurogenetics, and pathogenetics of left ventricular hypertrabeculation/noncompaction. *Pediatr Cardiol* 2009; 30: 659–681.